| *Sponsored
Low Float (Nasdaq: AMIX) Shares Breaking News Early Friday (New U.S. Patent Granted)
June 27th Greetings, Friend!
Autonomix Medical, Inc. (Nasdaq: AMIX) is claiming Friday's top watchlist spot.
Here's what to consider...
Earlier this morning, AMIX dropped some breaking news. Check it out:
Autonomix Medical, Inc. Granted New U.S. Patent for Innovative Catheter-Based Platform Technology
Patent supports the Company’s broader mission to advance minimally invasive, nerve-focused treatments across high-need indications
Strengthens strategic position in a multi-Bn-dollar market opp. and expands Autonomix’s growing global IP portfolio with over 80 issued patents
THE WOODLANDS, TX, June 27, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,279,889 B2 (the ‘889 patent) titled, “Systems and Methods for Neurological Traffic and/or Receptor Functional Evaluation and/or Modification.” The newly issued ‘899 patent relates to but is not limited to advanced systems and methods for locating, monitoring and mapping electrophysiological signals before, during and following a neuromodulation or denervation procedures. Furthermore, the patent explicitly contemplates tools to access small vessels and navigation to the target area to treat cancerous tumors and the pain associated with cancerous tumors. The technology is designed to treat conditions influenced by sympathetic nerve activity, including renal denervation for hypertension, chronic pain syndromes, cardiac modulation and metabolic and neurological disorders.
“This granted patent represents a significant step forward in our mission to improve patient outcomes by delivering more effective, less invasive treatments for conditions involving the nervous system, including chronic pain, autonomic dysfunction associated with hypertension and a range of other nerve-related disorders. We are pleased to strengthen our IP portfolio and further enhance our intellectual property position in the rapidly growing nerve-focused therapeutics space, enabling us to protect our innovations and deliver improved solutions for both clinicians and patients,” commented Brad Hauser, CEO of Autonomix.
...
Read the full article here.
Now, consider this strong news with AMIX's low float under 3Mn shares, and its 2 analyst targets suggesting triple-digit potential upside (more details below), and it's no surprise why this biotech idea currently tops my watchlist today.
Take a look at my initial (Nasdaq: AMIX) report below and consider this under-the-radar profile for your radar. -----
A dynamic biotech company is shaking up the industry by taking its novel approach to easing cancer-related pain to new heights.
Freshly cleared to widen its clinical study scope, the company is now pursuing various forms of visceral cancers, moving past its original concentration on pancreatic pain.
Initial data indicate notable improvements: less pain, reduced reliance on opioids, and enhanced daily living for those involved.
By leveraging a system that blends sophisticated nerve detection with precise ablation techniques, this company is uniquely equipped to tackle pressing pain control challenges.
As its clinical initiatives continue to grow, the company’s potential market could soon multiply, making it an intriguing prospect for close observation.
With a tight share float under 3Mn and a couple of analysts forecasting potential upside exceeding triple-digits, this Nasdaq-listed biotech could be worth a spot on your radar.
Take a moment—this is one to keep an eye on:
Autonomix Medical, Inc. (AMIX)
Autonomix is dedicated to transforming patient outcomes with its proprietary precision guidance technology, which is designed to sense, treat, and verify nerve activity.
By utilizing a minimally invasive procedure and novel nerve sensing technology, the company is able to identify and target specific nerves throughout the body.
Through its radio frequency (RF) ablation technology, Autonomix can then ablate responsible nerves and confirm that signaling has ceased.
This approach has the potential to revolutionize therapeutic electrophysiology and can be applied across a wide range of diseases, including chronic pain management, hypertension, and cardiology.
The Autonomix Mission
The mission of Autonomix is to dramatically improve the quality of life for millions by empowering the nerve-targeted treatments of tomorrow.
The company is committed to equipping physicians with innovative tools that enable unparalleled precision in diagnosis and treatment.
As a result, patients can expect more targeted therapies and a renewed sense of hope.
With its groundbreaking technology, Autonomix believes it can enable new procedures that were previously not possible.
Precision Approach to Pain Management
Autonomix Medical, Inc. is a medical device company focused on advancing precision nerve-targeted treatments to revolutionize the management of diseases involving the peripheral nervous system.
The company’s first-in-class platform system utilizes a catheter-based microchip sensing array antenna, which can detect and differentiate neural signals with up to 3,000 times greater sensitivity than currently available technologies.
Once target nerves are identified, Autonomix employs its proprietary radio frequency (RF) ablation technology to ablate those nerves, enabling a precision-guided sense, treat, and verify approach.
This technology addresses a broad spectrum of disease categories, from chronic pain management to hypertension and cardiology.
Autonomix is initially developing its precision nerve-targeted technology for the treatment of pain associated with pancreatic cancer.
Initial results from the company’s ongoing first-in-human study have demonstrated clinically meaningful and durable pain reduction in the first 15 responding patients.
Success in pancreatic cancer pain positions Autonomix to expand rapidly into additional cancer pain and abdominal pain indications, greatly increasing its potential market opp.
Grab Sources Here: AMIX Website. AMIX Presentation. -----
And based on multiple potential catalysts, (Nasdaq: AMIX) circles the top of my watchlist. Take a look...
#1. A Low Float Could Create Heightened Volatility Potential.
Yahoo Finance is reporting AMIX to have a float of approximately 2.4Mn shares.
What does that mean? It means that volatility potential could be significant on a daily basis.
#2. Two Analyst Targets Point To Triple-Digit Upside Potential For AMIX.
Not just one, but two different analysts are suggesting AMIX to be undervalued from current chart levels.
First off, Ladenburg Thalmann Co. Inc. analyst, Jeffrey S. Cohen, has tagged AMIX with an $18 target.
From its close on Thursday, that target provides AMIX with a potential upside of over 1,250%!
Additionally, Maxim Group analyst, Anthony Vendettii, has given AMIX a $5.00 target.
That target gives AMIX a potential upside of 250+% from its closing valuation Thursday.
#3. Autonomix Expands Clinical Trials To More Visceral Cancers.
Autonomix Medical, Inc. received Ethics Committee approval to broaden its proof-of-concept human clinical trial beyond pancreatic cancer pain, now including other visceral cancers.
This expansion, supported by promising early results, aims to double the addressable market and advance innovative nerve ablation technology for cancer pain management.
#4. Autonomix Secures Key Patent For Nerve Ablation Technology.
Autonomix Medical, Inc. announced a new patent for its nerve-targeted ablation technology, reinforcing its intellectual property position.
The patent supports ongoing clinical progress and bolsters the company’s strategy to address significant unmet needs in interventional pain management for cancer and other diseases.
#5. Autonomix Reports Positive Clinical Results And Patient Benefits.
Autonomix Medical, Inc. reported positive early results from its clinical trial in pancreatic cancer patients, demonstrating significant pain reduction, decreased opioid use, and improved quality of life.
These outcomes highlight the potential of its proprietary ablation technology to transform pain management for cancer patients with high unmet needs. -----
It's official. Coverage is now started on Autonomix Medical, Inc. (Nasdaq: AMIX).
When updates are available, I'll get them out quickly. Talk soon.
All the best, Dane James Editor Market Pulse Today
(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)
*MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 06/27/2025 and ending on 06/27/2025 to publicly disseminate information about (AMIX:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid seven thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (AMIX:US).
Please see important disclosure information here: https://marketpulsetoday.com/disclosure/amix-3echr/#details | 
0 Response to "Low Float (Nasdaq: AMIX) Shares Breaking News Early Friday (New U.S. Patent Granted)"
Post a Comment